WC2022 Programme Overview
(updated at 8 June 2022)
Programme is subject to change without prior notice.
Day 1Sunday, 12 Jun 2022 Day 2Monday, 13 Jun 2022 Day 3Tuesday, 14 Jun 2022 Day 4Wednesday, 15 Jun 2022 Day 5Thursday, 16 Jun 2022 Day 6Friday, 17 Jun 2022
DAY 3 Meet the Expert
Protein engineering for a “bio-better” next-generation therapeutic
Date: 14 Jun 2022
Time: 0830 - 1000hrs
Dr. Edward Wong, Product Manager, GenScript Asia Pacific (Singapore)
Dr. Edward Wong is the product manager in GenScript. He completed his Ph.D. degree from University of Adelaide. He worked as a Post Doctoral fellow at National Cancer Centre Singapore for 3 years and he had successfully reported the predictive factors for genetic screening of BRCA1 and BRCA2. He also reported the importance of genetic testing for 25 breast cancer-predisposition genes using NGS technology. Both of his works were reported in PlosOne and npj Genomic Medicine.
|Synopsis||Antibodies play a major role in supporting the life sciences from different aspects, including the use of antibody in detection assay and diagnostic tests or for therapeutic purposes. With the advent of advanced technology, we can now reach the targets that previously known as “undruggable” due to the availability of high diversity of antibodies. Nonetheless, to find the right candidates among the high diversity of antibodies can be laborious and time-consuming. Furthermore, the researcher would have experienced a number of challenges, including the missing out on good binders, poor antibody library coverage, throughout the discovery and development workflow.
Several attempts have been made to address these challenges. Among these attempts, the affinity maturation is an important strategy in antibody optimization to generate safe and efficacious second-generation therapeutics. The recent development of synthetic biology provides the breakthrough that allow the researchers to precisely define and control the synthesis of high-diversity domain libraries. The optimization process usually requires several rounds of the mutant library construction and screening in order to isolate the top ideal candidate. The benefit of identifying the improved antibody, in a higher specificity and affinity, can help to enhance a higher success rate in the clinic while reducing in cost to the patient due to a smaller and infrequent dosing.
A) How we can rapidly identify and validate a diverse repertoire of high-affinity antibodies?
B) How we can further improve the binding affinity of the antibody while reducing the screening burden during the optimization process?